Latham’s Washington, D.C. office offers clients powerhouse corporate capabilities, regulatory insights, as well as litigation and trial strength.
We have built a remarkable track record of navigating the federal government — in the courts, the White House and Executive Branch agencies, as well as Congress. As a group, we draw on experience serving in a wide variety of senior roles within the federal government, so we can advise clients based on deep knowledge of the inner workings of government.
We regularly represent clients facing criminal, civil, and congressional investigations, litigation in all US courts, and the full range of commercial disputes. Our courtroom victories regularly earn Latham recognition from National Law Journal as among the very best litigators and trial lawyers in Washington.
Unique among firms in the capital, we combine classic litigation and regulatory practices with our premier transactional practices, which include the largest and most successful corporate/M&A, capital markets, private equity, and leveraged finance practices in Washington.
As one of the world’s largest pro bono providers, Latham takes on matters in nearly every area of public interest law. In Washington, D.C., some of our key pro bono causes include advocating for asylum seekers, reuniting immigrant and refugee families, and safeguarding tenants’ rights, veterans’ rights, and civil rights.
A Latham Securities and M&A Litigation team achieved a win in the Delaware Court of Chancery on behalf of client Novo Nordisk.
Two Latham Securities and M&A Litigation teams notched wins in Delaware Chancery Court: one successfully voided board changes on behalf of minority shareholders in a Section 225 action, and another secured dismissal of all claims for a client group affiliated with private equity firms in a de-SPAC case.
A Latham team led by partners Michael Bern, Steve Feldman, and Matthew Walch, earned recognition in The American Lawyer’s Litigators of the Week column for their rare reversal in the Second Circuit for client Zesty Paws. The court unanimously vacated a preliminary injunction that had barred Zesty Paws from advertising itself as the “#1 brand” of pet supplements sold in the United States.